Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Regeneron Advances Two Factor XI Antibodies to Phase 3 Following Successful Phase 2 Results
Latest Hotspot
3 min read
Regeneron Advances Two Factor XI Antibodies to Phase 3 Following Successful Phase 2 Results
25 December 2024
Regeneron will move forward with two Factor XI antibodies into an extensive Phase 3 program after successful Phase 2 proof-of-concept outcomes.
Read →
Vittoria Biotherapeutics Begins Phase 1 Trial Dosing for VIPER-101
Latest Hotspot
3 min read
Vittoria Biotherapeutics Begins Phase 1 Trial Dosing for VIPER-101
25 December 2024
Vittoria Biotherapeutics has commenced dosing the initial patient in the Phase 1 clinical trial for VIPER-101.
Read →
U.S. Approves TRYNGOLZA™ (olezarsen) as First Treatment for Familial Chylomicronemia Syndrome in Adults
Latest Hotspot
3 min read
U.S. Approves TRYNGOLZA™ (olezarsen) as First Treatment for Familial Chylomicronemia Syndrome in Adults
25 December 2024
TRYNGOLZA™ (olezarsen) has received U.S. approval as the first treatment for adults with familial chylomicronemia syndrome, used alongside dietary changes.
Read →
Vertex Announces Phase 2 Results for Suzetrigine in Treating Painful Lumbar Radiculopathy
Latest Hotspot
3 min read
Vertex Announces Phase 2 Results for Suzetrigine in Treating Painful Lumbar Radiculopathy
25 December 2024
Vertex Reports Outcomes from Phase 2 Trial of Suzetrigine for Painful Lumbar Radiculopathy Treatment.
Read →
Dosing of First Patient in Adicet Bio's ADI-270 Phase 1 Trial for Advanced Renal Cancer
Latest Hotspot
2 min read
Dosing of First Patient in Adicet Bio's ADI-270 Phase 1 Trial for Advanced Renal Cancer
25 December 2024
Adicet Bio has reported the dosing of the initial patient in a Phase 1 clinical trial for ADI-270 targeting metastatic/advanced clear cell renal cell carcinoma.
Read →
Narsoplimab by Omeros Demonstrates Improved Survival in TA-TMA Patients, Meets Key Trial Milestone
Latest Hotspot
4 min read
Narsoplimab by Omeros Demonstrates Improved Survival in TA-TMA Patients, Meets Key Trial Milestone
25 December 2024
Omeros' Narsoplimab Achieves Key Trial Goal – Data Analysis Reveals Better Survival Compared to External Control in TA-TMA Patients.
Read →
Favorable Phase 1b Results for Sorriso's SOR102 in Ulcerative Colitis Treatment
Latest Hotspot
4 min read
Favorable Phase 1b Results for Sorriso's SOR102 in Ulcerative Colitis Treatment
25 December 2024
Sorriso Pharmaceuticals Reveals Favorable Phase 1b Trial Results for SOR102 in Treating Ulcerative Colitis.
Read →
Targeting Nectin-4: The Rise of Enfortumab Vedotin in ADC Cancer Therapy
Bio Sequence
7 min read
Targeting Nectin-4: The Rise of Enfortumab Vedotin in ADC Cancer Therapy
24 December 2024
In recent years, a molecular target called Nectin-4 has emerged as a rising star in the field of anti-cancer drug development.
Read →
Accord Healthcare Gains Approval for IMULDOSA®, a Stelara® Biosimilar
Latest Hotspot
3 min read
Accord Healthcare Gains Approval for IMULDOSA®, a Stelara® Biosimilar
20 December 2024
Accord Healthcare has received approval to market IMULDOSA®, a biosimilar of ustekinumab, which is similar to Stelara®.
Read →
SpliceBio Gets FDA Clearance for SB-007 in Stargardt Disease Trials
Latest Hotspot
3 min read
SpliceBio Gets FDA Clearance for SB-007 in Stargardt Disease Trials
20 December 2024
SpliceBio has received IND clearance from the U.S. FDA for SB-007, allowing the start of Phase 1/2 clinical trials in Stargardt Disease patients.
Read →
Elevation Oncology Expands Pipeline with HER3-Targeting ADC EO-1022 for Solid Tumors
Latest Hotspot
3 min read
Elevation Oncology Expands Pipeline with HER3-Targeting ADC EO-1022 for Solid Tumors
20 December 2024
Elevation Oncology broadens its pipeline with the introduction of EO-1022, a HER3 ADC aimed at treating solid tumors that express HER3.
Read →
FDA Approves Neurocrine's CRENESSITY™ for Congenital Adrenal Hyperplasia
Latest Hotspot
3 min read
FDA Approves Neurocrine's CRENESSITY™ for Congenital Adrenal Hyperplasia
20 December 2024
Neurocrine Biosciences has received FDA approval for CRENESSITY™ (crinecerfont), the first of its kind therapy for both children and adults suffering from classic congenital adrenal hyperplasia.
Read →